The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Systematic identification of genomic markers of drug sensitivity in cancer cells
Open accessAbstract
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutated cancer genes were associated with cellular response to most currently available cancer drugs. Classic oncogene addiction paradigms were modified by additional tissue-specific or expression biomarkers, and some frequently mutated genes were associated with sensitivity to a broad range of therapeutic agents. Unexpected relationships were revealed, including the marked sensitivity of Ewing's sarcoma cells harbouring the EWS (also known as EWSR1)-FLI1 gene translocation to poly(ADP-ribose) polymerase (PARP) inhibitors. By linking drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [150]
In the citing paper
“BRAF mutation was associated with nutlin 3a sensitivity in the same study130.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“p53 mutation status was the strongest indicator of nutlin 3a resistance”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“Even with such a simple readout, genes and pathways that determine drug response can be identified,199,200”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [199]
In the citing paper
“More than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger’s GDSC project (5, 18) as well as cell models generated as part of the Human Cancer Models Initiative.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,004
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 135
Self-citationPredicting tumor cell line response to drug pairs with deep learning
Xia, F., Shukla, M. P., Brettin, T. S., García–Cardona, C., Cohn, J. D., Allen, J., Maslov, S., Holbeck, S. L., Doroshow, J. H., Evrard, Y. A., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2509-3 · Cited by 128
Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data
Torre, C. F., Jiménez‐Santos, M. J., García‐Martín, S., Carretero-Puche, C., García-Jimeno, L., Ivanchuk, V., Domenico, T. D., Goméz-López, G., & Al‐Shahrour, F. (2021) · Genome Medicine · doi:10.1186/s13073-021-01001-x · Cited by 131
He, Y., Zhu, Q., Chen, M., Huang, Q., Wang, W., Li, Q., Huang, Y., & Di, W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12223 · Cited by 136
CancerDR: Cancer Drug Resistance Database
Kumar, R., Chaudhary, K., Gupta, S., Singh, H., Kumar, S., Gautam, A., Kapoor, P., & Raghava, G. P. S. (2013) · Scientific Reports · doi:10.1038/srep01445 · Cited by 129
Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel
Cortés‐Ciriano, I., van Westen, G. J. P., Bouvier, G., Nilges, M., Overington, J. P., Bender, A., & Malliavin, T. E. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv529 · Cited by 123
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
Picco, G., Chen, E. D., García‐Alonso, L., Behan, F. M., Gonçalves, E., Bignell, G. R., Matchan, A., Fu, B., Banerjee, R., Anderson, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09940-1 · Cited by 128
Self-citationGao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X., Worthley, D. L., Wang, X.-Y., Niu, G., Xia, Y., Deng, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.008 · Cited by 128
Zheng, X., Vis, D. J., Bruna, A., Šuštić, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 123
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Self-citationVougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 129
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
“tivity data from a comprehensive cancer cell line screen (22).”
BackgroundSelf-citationNakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 121
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Vizoso, M., Ferreira, H. J., López-Serra, P., Carmona, F. J., Martínez‐Cardús, A., Girotti, M. R., Villanueva, A., Guil, S., Moutinho, C., Liz, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3863 · Cited by 123
Self-citationSmith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R. G., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2572 · Cited by 122
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 123
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting
Iorio, F., Behan, F. M., Gonçalves, E., Bhosle, S. G., Chen, E. D., Shepherd, R., Beaver, C., Ansari, R. A., Pooley, R., Wilkinson, P., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-4989-y · Cited by 120
Self-citationArtificial intelligence in drug combination therapy
Tsigelny, I. F. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby004 · Cited by 124
Iskar, M., Zeller, G., Blattmann, P., Campillos, M., Kuhn, M., Kaminska, K. H., Runz, H., Gavin, A., Pepperkok, R., van Noort, V., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.20 · Cited by 118
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Ammad-ud-din, M., Khan, S. A., Malani, D., Murumägi, A., Kallioniemi, O., Aittokallio, T. A., & Samuel Kaski, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw433 · Cited by 116
Inhibitors of PARP: Number crunching and structure gazing
Rudolph, J., Jung, K., & Luger, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121979119 · Cited by 121
The SOX family of genes in cancer development: biological relevance and opportunities for therapy
Castillo, S. D., & Sánchez‐Céspedes, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.709239 · Cited by 117
Tokarz, P., & Błasiak, J. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2079 · Cited by 117
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
López-Serra, P., Marcilla, M., Villanueva, A., Ramos-Fernández, A., Palau, A., Leal, L., Wahi, J. E., Setien-Baranda, F., Szczęsna, K., Moutinho, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4608 · Cited by 118
Self-citationPredictive approaches for drug combination discovery in cancer
Tonekaboni, S. A. M., Ghoraie, L. S., Manem, V. S., & Haibe‐Kains, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 118
Recent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 122
Cortés‐Ciriano, I., Ain, Q. U., Subramanian, V., Lenselink, E. B., Méndez‐Lucio, O., IJzerman, A. P., Wohlfahrt, G., Prūsis, P., Malliavin, T. E., van Westen, G. J. P., et al. (2014) · MedChemComm · doi:10.1039/c4md00216d · Cited by 119
Li, H., Wawrose, J. S., Gooding, W. E., Garraway, L. A., Lui, V. W. Y., Peyser, N. D., & Grandis, J. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0396 · Cited by 116
Su, C., Lv, Y., Lu, W., Yu, Z., Ye, Y., Guo, B., Liu, D., Yan, H., Li, T., Zhang, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719564 · Cited by 123
Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells
Roumeliotis, T. I., Williams, S. P., Gonçalves, E., Alsinet, C., Velasco‐Herrera, M. D. C., Aben, N., Ghavidel, F. Z., Michaut, M., Schubert, M., Price, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.010 · Cited by 108
Self-citationHagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., Wickstroem, K., Schatz, C. A., Kneip, C., Golfier, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3476 · Cited by 117
Picco, G., Cattaneo, C. M., van Vliet, E. J., Crisafulli, G., Rospo, G., Consonni, S., Vieira, S. F., Sánchez-Rodríguez, I., Cancelliere, C., Banerjee, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1508 · Cited by 112
Self-citationIntegrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization
Ammad-ud-din, M., Georgii, E., Gönen, M., Laitinen, T., Kallioniemi, O., Wennerberg, K., Poso, A., & Samuel Kaski, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500152b · Cited by 114
Weyburne, E. S., Wilkins, O. M., Sha, Z., Williams, D. A., Pletnev, A. A., de Bruin, G., Overkleeft, H. S., Goldberg, A. L., Cole, M. D., & Kisselev, A. F. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2016.12.016 · Cited by 111
Machine Learning in Oncology: Methods, Applications, and Challenges
Bertsimas, D., & Wiberg, H. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00072 · Cited by 121
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 113
An, Ö., Dall’Olio, G. M., Mourikis, T. P., & Ciccarelli, F. D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1123 · Cited by 106
Cheng, F., Jia, P., Wang, Q., & Zhao, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1984 · Cited by 105
Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
Chen, Z., Lan, X., Wu, D., Sunkel, B. D., Ye, Z., Huang, J., Liu, Z., Clinton, S. K., Jin, V. X., & Wang, Q. (2015) · Nature Communications · doi:10.1038/ncomms9323 · Cited by 110
Hybrid Quantum Neural Network for Drug Response Prediction
Sagingalieva, A., Kordzanganeh, M., Kenbaev, N. R., Kosichkina, D., Tomashuk, T., & Melnikov, A. A. (2023) · Cancers · doi:10.3390/cancers15102705 · Cited by 129
Baldassi, C., Alemi, A., Pagan, M., DiCarlo, J. J., Zecchina, R., & Zoccolan, D. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003167 · Cited by 110
Zeng, Y., Ren, J., Shen, A., & Hu, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04892 · Cited by 109
Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How
Bröer, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176156 · Cited by 116
Stadler, M., Pudelko, K., Biermeier, A., Walterskirchen, N., Gaigneaux, A., Weindorfer, C., Harrer, N. E., Klett, H., Hengstschläger, M., Schüler, J. B., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.006 · Cited by 116
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Libério, M. S., Walther, T., et al. (2017) · Kölner Universitäts PublikationsServer (Universität zu Köln) · doi:10.17863/cam.20903 · Cited by 111
Targeting the histone orthography of cancer: drugs for writers, erasers and readers
Simó‐Riudalbas, L., & Esteller, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12844 · Cited by 111
The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils
Stammnitz, M. R., Coorens, T. H. H., Gori, K. C., Hayes, D., Fu, B., Wang, J., Martin-Herranz, D. E., Alexandrov, L. B., Baez‐Ortega, A., Barthorpe, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.013 · Cited by 107
Self-citationIntegrated Computational Approaches and Tools for Allosteric Drug Discovery
Amamuddy, O. S., Veldman, W., Manyumwa, C. V., Khairallah, A., Agajanian, S., Odeyemi, O., Verkhivker, G. M., & Bishop, Ö. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030847 · Cited by 107
Weinstein, J. N. (2012) · Nature · doi:10.1038/483544a · Cited by 109
Basal Cell Signaling by p63 Controls Luminal Progenitor Function and Lactation via NRG1
Forster, N., Saladi, S. V., van Bragt, M. P. A., Sfondouris, M. E., Jones, F. E., Li, Z., & Ellisen, L. W. (2014) · Developmental Cell · doi:10.1016/j.devcel.2013.11.019 · Cited by 107
Zaman, N., Li, L., Jaramillo, M. L., Sun, Z., Tibiche, C., Banville, M., Collins, C., Trifiro, M. A., Paliouras, M., Nantel, A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.028 · Cited by 111
Improving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
Multitask learning improves prediction of cancer drug sensitivity
Yuan, H., Paskov, I., Paskov, H. S., González, A. J., & Leslie, C. S. (2016) · Scientific Reports · doi:10.1038/srep31619 · Cited by 104
Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
Stefánsson, Ó. A., & Esteller, M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.033 · Cited by 111
Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R. P., Yarar, D., Paragas, V. B., Pace, E. A., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 107
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response
Nickerson, M., Witte, N., Im, K. M., Turan, S., Owens, C. R., Misner, K., Tsang, S. X., Cai, Z., Wu, S., Dean, M. C., et al. (2016) · Oncogene · doi:10.1038/onc.2016.172 · Cited by 106
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodrı́guez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 104
Bhatia, S., Kramer, M., Russo, S., Naik, P., Arun, G., Brophy, K., Andrews, P., Fan, C., Perou, C. M., Preall, J. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2807 · Cited by 103
“Omics” in pharmaceutical research: overview, applications, challenges, and future perspectives
Yan, S., Liu, R., Jin, H., Liu, X., Ye, J., Shan, L., & Zhang, W. (2015) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(15)60002-4 · Cited by 115
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma
Lochmann, T. L., Powell, K. M., Ham, J., Floros, K. V., Heisey, D. A. R., Kurupi, R., Calbert, M. L., Ghotra, M. S., Greninger, P., Dozmorov, M. G., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4680 · Cited by 103
Self-citationPredicting Drug Response Based on Multi-Omics Fusion and Graph Convolution
Peng, W., Chen, T., & Dai, W. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3102186 · Cited by 104
Uitdehaag, J. C. M., de Roos, J. A. D. M., van Doornmalen, A. M., Prinsen, M. B. W., de Man, J., Tanizawa, Y., Kawase, Y., Yoshino, K., Buijsman, R. C., & Zaman, G. J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092146 · Cited by 105
Pancreatic cancer subtypes: a roadmap for precision medicine
Torres, C., & Grippo, P. J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1453168 · Cited by 104
O'Sullivan, C. C., Moon, D. H., Kohn, E. C., & Lee, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00042 · Cited by 106
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Tang, S.-W., Bilke, S., Cao, L., Murai, J., Sousa, F. G., Yamade, M., Rajapakse, V. N., Varma, S., Helman, L. J., Khan, J. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2112 · Cited by 105
Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs
Santo, V. E., Rebelo, S. P., Estrada, M. F., Alves, P. M., Boghaert, E. R., & Brito, C. (2016) · Biotechnology Journal · doi:10.1002/biot.201600505 · Cited by 110
Eduati, F., Doldàn-Martelli, V., Klinger, B., Cokelaer, T., Sieber, A., Kogera, F., Dorel, M., Garnett, M. J., Blüthgen, N., & Sáez-Rodríguez, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0078 · Cited by 97
Self-citationDrug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning
Gönen, M., & Margolin, A. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu464 · Cited by 102
High-resolution network biology: connecting sequence with function
Ryan, C. J., Cimermančič, P., Szpiech, Z. A., Šali, A., Hernandez, R. D., & Krogan, N. J. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3574 · Cited by 98
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y.-S., Costa-Cabral, S., Frankum, J. R., Gulati, A., Holme, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.023 · Cited by 104
Rouette, A., Trofimov, A., Haberl, D., Boucher, G., Lavallée, V., D’Angelo, G., Hébert, J., Sauvageau, G., Lemieux, S., & Perreault, C. (2016) · Scientific Reports · doi:10.1038/srep34019 · Cited by 106
Kaushik, A. M., Hsieh, K., & Wang, T. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1522 · Cited by 105
den Bossche, V. V., Zaryouh, H., Vara-Messler, M., Vignau, J., Machiels, J., Wouters, A., Schmitz, S., & Corbet, C. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100806 · Cited by 105
Liu, Q., Ghosh, P., Magpayo, N., Testa, M., Tang, S., Gheorghiu, L., Biggs, P. J., Paganetti, H., Efstathiou, J. A., Lu, H., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.046 · Cited by 101
Self-citationToward A variable RBE for proton beam therapy
Willers, H., Allen, A. R., Grosshans, D. R., McMahon, S. J., von Neubeck, C., Wiese, C., & Vikram, B. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.019 · Cited by 101
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
Gonçalves, E., Segura‐Cabrera, A., Pacini, C., Picco, G., Behan, F. M., Jaaks, P., Coker, E. A., van der Meer, D., Barthorpe, A. S., Lightfoot, H. W., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199405 · Cited by 106
Self-citationEnhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Hatzis, C., Bedard, P. L., Birkbak, N. J., Beck, A. H., Aerts, H. J. W. L., Stern, D. F., Shi, L. M., Clarke, R. C., Quackenbush, J. F., & Haibe‐Kains, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0725 · Cited by 96
Targeting glutamine metabolism slows soft tissue sarcoma growth
Lee, P., Malik, D. M., Perkons, N. R., Huangyang, P., Khare, S., Rhoades, S. D., Gong, Y.-Y., Burrows, M., Finan, J. M., Nissim, I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14374-1 · Cited by 105
Cancer research needs a better map
Boehm, J. S., Garnett, M. J., Adams, D. J., Francies, H. E., Golub, T. R., Hahn, W. C., Iorio, F., McFarland, J. M., Parts, L., & Vázquez, F. (2021) · Nature · doi:10.1038/d41586-021-00182-0 · Cited by 96
Self-citationFallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Self-citationGupta, A., Ajith, A., Singh, S., Panday, R. K., Samaiya, A., & Shukla, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0887-0 · Cited by 98
Liu, Q., Ma, L., Jones, T., Palomero, L., Pujana, M. Á., Martinez‐Ruiz, H., Ha, P. K., Murnane, J. P., Cuartas, I., Seoane, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1346 · Cited by 100
Self-citationGenetic characterization of ABT-199 sensitivity in human AML
Bisaillon, R., Moison, C., Thiollier, C., Krošl, J., Bordeleau, M.-È., Lehnertz, B., Lavallée, V., MacRae, T., Mayotte, N., Labelle, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0485-x · Cited by 105
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 101
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
Guan, N., Zhao, Y. F., Wang, C.-C., Li, J., Chen, X., & Piao, X. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.017 · Cited by 96
miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression
Zhang, H., Qi, S., Zhang, T., Wang, A., Liu, R., Guo, J., Wang, Y. Z., & Xu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3341 · Cited by 96
Self-citationSukhai, M. A., Craddock, K. J., Thomas, M., Hansen, A. R., Zhang, T., Siu, L. L., Bedard, P. L., Stockley, T. L., & Kamel‐Reid, S. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.47 · Cited by 98
Self-citationNew drugs for children and adolescents with cancer: the need for novel development pathways
Vassal, G., Zwaan, C. M., Ashley, D. M., Deley, M. L., Hargrave, D. R., Blanc, P., & Adamson, P. C. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70013-5 · Cited by 101
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines
Papp, E., Hallberg, D. L., Konecny, G. E., Bruhm, D. C., Adleff, V., Noë, M., Kagiampakis, I., Palsgrove, D. N., Conklin, D. F., Kinose, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.096 · Cited by 97
Whaley, J. J. J., Afkhami, M., Onyshchenko, M. I., Massarelli, E., Sampath, S., Amini, A., Bell, D., & Villaflor, V. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01101-3 · Cited by 100
Niepel, M., Hafner, M. A., Duan, Q., Wang, Z., Paull, E., Chung, M., Lü, X., Stuart, J. M., Golub, T. R., Subramanian, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01383-w · Cited by 93
AlQuraishi, M., & Sorger, P. K. (2021) · Nature Methods · doi:10.1038/s41592-021-01283-4 · Cited by 96
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero‐Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual‐Pasto, G., San‐Segundo, L., Vilà-Ubach, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4303 · Cited by 95
Yu, D., Zhang, S., Feng, A., Xu, D., Zhu, Q., Mao, Y., Zhao, Y., Lv, Y., Han, C., Liu, R., et al. (2019) · Medicine · doi:10.1097/md.0000000000015582 · Cited by 99
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Schoeberl, B., & Sorger, P. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004379 · Cited by 93
Metadata
- Authors
- Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O’Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., & Benes, C. H.
- Affiliations
- Wellcome Sanger Institute (GB)
- Harvard University (US)
- European Bioinformatics Institute (GB)
- Institut Curie (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Howard Hughes Medical Institute (US)
- Corresponding author
- McDermott, Ultan
- Benes, Cyril H.
- ORCID
- Garnett, Mathew J.
- Greenman, Chris D.
- Dastur, Anahita
- Lau, King Wai
- Greninger, Patricia
- Thompson, I. Richard
- Luo, Xi
- Liu, Qingsong
- Iorio, Francesco
- Surdez, Didier
- Chen, Li
- Davies, Helen
- Barthorpe, Syd
- Lawrence, Karl
- Mironenko, Tatiana
- Richardson, Laura
- Zhou, Wenjun
- Zhang, Tinghu
- O’Brien, Patrick
- Hur, Wooyoung
- Yang, Wanjuan
- Deng, Xianming
- Choi, Hwan Geun
- Chang, Jae Won
- Baselga, Jose
- Stamenkovic, Ivan
- Engelman, Jeffrey A.
- Delattre, Olivier
- Gray, Nathanael S.
- Settleman, Jeffrey
- Futreal, P. Andrew
- Haber, Daniel A.
- Stratton, Michael R.
- McDermott, Ultan
- Benes, Cyril H.
- Venue
- Nature
- Published
- 2012-03
- Volume
- 483
- Issue
- 7391
- Pages
- 570-575
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3349233
- OpenAlex
- W2125789330
- Cited by
- 2,456
- References
- 39
- Citations by year
- 2026: 106 · 2025: 101 · 2024: 114 · 2023: 145 · 2022: 161 · 2021: 228 · 2020: 162 · 2019: 183 · 2018: 212 · 2017: 198 · 2016: 214 · 2015: 199 · 2014: 197 · 2013: 153 · 2012: 82
- FWCI
- 66.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- IRIS (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Wellcome Trust (086357)
- Cancer Research UK
- National Institutes of Health (5u54hg006097-03)
- National Human Genome Research Institute (1U54HG006097-01, U54-HG006097)
- National Institute of General Medical Sciences (P41GM079575)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- drug sensitivity, drug resistance, pharmacogenomics, cancer cell lines, genomic biomarkers, oncogene addiction, Ewing sarcoma, PARP inhibitors, topoisomerase inhibitors, SLFN11, tissue-specific biomarkers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Cell Survival, Drug Screening Assays, Antitumor, Genetic Markers, Humans, Indoles, Neoplasms, Pharmacogenetics, Phthalazines, Piperazines, Sarcoma, Ewing, Oncogene Proteins, Fusion, Genome, Human, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Genomics, RNA-Binding Protein EWS, Cell Line, Tumor, Proto-Oncogene Protein c-fli-1, Genes, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
